<DOC>
	<DOCNO>NCT02074878</DOCNO>
	<brief_summary>Crizotinib medication take mouth . It show help slow stop growth tumor cell . The marketing name drug `` Xalkori '' . It approve FDA ( Food Drug Administration ) treat type metastatic cancer , investigator believe may helpful treat breast cancer well . Sunitinib medication use study . It also take mouth form capsule . The marketing name drug `` Sutent '' . It approve FDA treat type cancer , breast cancer . In study investigator combine two treatment , different dos . One third patient take Crizotinib 200 mg , twice daily Sunitinib 25.0 mg day . One third patient take Crizotinib 250 mg , twice daily Sunitinib 25.0 mg day , One third patient take Crizotinib 250 mg , twice daily Sunitinib 37.5 mg day .</brief_summary>
	<brief_title>CRIZENT : Crizotinib Sunitinib Metastatic Breast Cancer</brief_title>
	<detailed_description>This study determine safety tolerability combination crizotinib sunitinib treatment Metastatic Breast Cancer help establish maximum tolerate dose future phase II study combination .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>1 . Subjects must provide write informed consent prior performance studyspecific procedures assessment , must willing comply treatment followup . 2 . Age least 18 year 3 . Histologically confirm diagnosis stage IV , HER2 negative breast cancer . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . 5 . Patients must fail two line systemic therapy breast cancer . Patients hormone receptor positive must fail least one line hormonal therapy AND one line chemotherapy metastatic setting . 6 . Life expectancy 6 month . 7 . Liver function ( ALT , AST , alkaline phosphatase , total bilirubin ) kidney function test ( BUN , creatinine ) less 2.5 time upper limit normal . In patient liver metastasis , liver function test less 5 time upper limit normal . 8 . Adequate blood count ( Hemoglobin great than/equal 10 , WBC great than/equal 3.0 , platelet great than/equal 100 ) . 9 . The patient normal thyroid function test ( TSH , free T4 ) define test laboratory , test abnormality asymptomatic warrant medical intervention , preexist thyroid disorder control medical treatment . 10 . Negative pregnancy test ( BHCG ) within 14 day study drug initiation pre perimenopausal subject intact uterus . 1 . Clinically significant gastrointestinal abnormality may increase risk gastrointestinal bleeding . 2 . Clinically significant gastrointestinal abnormality may affect absorption investigational product . 3 . Presence uncontrolled infection . 4 . Corrected QT interval ( QTc ) &gt; 480 msec use Bazett 's formula 5 . History one follow cardiovascular condition within past 6 month : Cardiac angioplasty stenting Myocardial infarction Unstable angina Coronary artery bypass graft surgery Symptomatic peripheral vascular disease Class III IV congestive heart failure , define New York Heart Association ( NYHA ) 6 . Poorly control hypertension ( define systolic blood pressure [ SBP ] &gt; 150 mmHg diastolic blood pressure [ DBP ] &gt; 90 mmHg ) . 7 . History cerebrovascular accident include transient ischemic attack ( TIA ) , pulmonary embolism , untreated deep venous thrombosis ( DVT ) within past 6 month . Subjects recent DVT treat therapeutic anticoagulating agent least 6 week eligible . 8 . Prior major surgery trauma within 28 day prior first dose study drug and/or presence nonhealing wound , fracture , ulcer ( procedure catheter placement consider major ) . 9 . Evidence active bleeding bleed diathesis . 10 . Known endobronchial lesion and/or lesion infiltrate major pulmonary vessel 11 . Hemoptysis excess 2.5 mL ( one half teaspoon ) within 8 week prior first dose study drug . 12 . Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance study procedure . 13 . Patients previously treat sunitinib crizotinib . 14 . History malignancy within last 5 year , except carcinoma situ cervix basal cell carcinoma skin . 15 . Concurrent use : Potent CYP3A4 inhibitor : ketoconazole , itraconazole , clarithromycin , atazanavir , nefazodone , saquinavir , telithromycin , ritonavir , amprenavir , indinavir , nelfinavir , delavirdine voriconazole . CYP3A4 inducer : rifampin , rifabutin , rifapentin , phenobarbital , phenytoin , carbamazepine , St. John 's Wort , dexamethasone . Use dexamethasone study premedication allow . Grapefruit grapefruit juice . ( Note : Alternative therapy use available . If use potent CYP3A4 inhibitor inducer necessary , must approve principal investigator document source document ) . 16 . History receive investigational treatment within 28 day study medication initiation . 17 . Current severe , uncontrolled systemic disease ( e.g. , clinically significant cardiovascular , pulmonary , thyroid , metabolic disease ; wound heal disorder ; ulcer ; bone fracture ) . 18 . Patients pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Crizotinib</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Xalcori</keyword>
	<keyword>Sutent</keyword>
</DOC>